Ping An Securities·2026-02-04 13:20Investment Rating - The report maintains a "Recommendation" rating for the company, indicating an expectation that the stock will outperform the market by 10% to 20% over the next six months [10]. Core Insights - The company is expected to achieve a revenue of 2.371 billion yuan in 2025, representing a year-on-year growth of approximately 134%. Additionally, it is projected to turn a profit with a net profit of around 630 million yuan, primarily due to the continued commercialization of products and income from business development [4][8]. - The company has multiple products in the market, including Obinutuzumab, which is seeing increasing sales. The company is also expanding its global collaboration efforts, having secured two licensing agreements in 2025, which will provide upfront payments and milestone revenues [7][8]. Financial Summary - Revenue projections for the company are as follows: - 2023: 739 million yuan - 2024: 1.009 billion yuan - 2025: 2.371 billion yuan - 2026: 2.575 billion yuan - 2027: 2.732 billion yuan - Year-on-year growth rates are projected at 18.1% for 2023, 36.7% for 2024, and 134.9% for 2025, followed by 8.6% and 6.1% for 2026 and 2027 respectively [6][8]. - The company is expected to achieve a gross margin of 98.0% in 2025, with a net margin of 27.4% [6][8]. - The company's total assets are projected to reach 10.888 billion yuan by 2025, with total liabilities of 3.491 billion yuan [9].